Epidemiology and comorbidity of hidradenitis suppurativa in Korea for 17 years: A nationwide population-based cohort study
Jong Won Lee
Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Korea
Search for more papers by this authorYeon-Woo Heo
Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Korea
Search for more papers by this authorJi Hae Lee
Department of Dermatology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea
Search for more papers by this authorCorresponding Author
Solam Lee
Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Korea
Correspondence
Solam Lee, Department of Dermatology, Yonsei University Wonju College of Medicine, Ilsan-ro 20, Wonju 26426, Korea.
Email: [email protected]
Search for more papers by this authorJong Won Lee
Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Korea
Search for more papers by this authorYeon-Woo Heo
Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Korea
Search for more papers by this authorJi Hae Lee
Department of Dermatology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea
Search for more papers by this authorCorresponding Author
Solam Lee
Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Korea
Correspondence
Solam Lee, Department of Dermatology, Yonsei University Wonju College of Medicine, Ilsan-ro 20, Wonju 26426, Korea.
Email: [email protected]
Search for more papers by this authorAbstract
Hidradenitis suppurativa (HS) is associated with various metabolic and autoimmune diseases. The epidemiology has been analyzed in various studies worldwide. However, epidemiological data on HS for Asian populations are limited. This study aimed to analyze the change in the prevalence and incidence of HS over 17 years in South Korea using the Korean National Health Insurance Service (NHIS) database. This study also evaluated the comorbidities in patients with HS. Population-based data from the NHIS database of Korea were obtained between January 2003 and December 2019. Odds ratios were estimated to determine the association between comorbidities and HS during the study period. Hazard ratios for the risk of incident comorbidities in patients with HS were obtained using the multivariable Cox proportional hazard analysis. This study included 45 511 patients with HS and 910 220 controls matched for age, sex, insurance type, and income level. The incidence rate of HS per 1 000 000 person-years in Korea increased from 11.69 in 2003 to 78.78 in 2019. The annual prevalence per 1 000 000 people also increased from 34.68 in 2003 to 140.10 in 2019, showing a similar trend. Many comorbidities, including atopic, metabolic and end-organ, autoimmune/inflammatory, and psychiatric diseases were associated with HS at baseline. In many diseases, the risk of incident comorbidities in patients with HS was higher than that in controls. The incidence and prevalence of HS in Korea have increased over the past 17 years. Various comorbidities, including allergic diseases, hypertension, diabetes mellitus, dyslipidemia, myocardial infarction, chronic hepatitis and cirrhosis, chronic kidney disease, inflammatory bowel diseases, rheumatoid arthritis, vitamin D deficiency, and psychiatric diseases, were associated with HS. Physicians need to keep in mind and closely monitor these comorbidities in patients with HS.
CONFLICT OF INTEREST STATEMENT
The authors have no conflict of interest to declare.
References
- 1Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020; 82: 1045–58.
- 2Ingram JR. The epidemiology of hidradenitis suppurativa. Br J Dermatol. 2020; 183: 990–8.
- 3Sampogna F, Fania L, Mastroeni S, Ciccone D, Panebianco A, Abeni D. Age-specific physical and mental health status in Italian patients with hidradenitis suppurativa: a comparison with the general population. Arch Dermatol Res. 2021; 313: 41–7.
- 4Nguyen TV, Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2021; 35: 50–61.
- 5Garg A, Malviya N, Strunk A, Wright S, Alavi A, Alhusayen R, et al. Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian hidradenitis suppurativa foundations. J Am Acad Dermatol. 2022; 86: 1092–101.
- 6Kohorst JJ, Kimball AB, Davis MD. Systemic associations of hidradenitis suppurativa. J Am Acad Dermatol. 2015; 73(5 Suppl 1): S27–35.
- 7Kirsten N, Petersen J, Hagenstrom K, Augustin M. Epidemiology of hidradenitis suppurativa in Germany - an observational cohort study based on a multisource approach. J Eur Acad Dermatol Venereol. 2020; 34: 174–9.
- 8Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996; 35(2 Pt 1): 191–4.
- 9Garg A, Lavian J, Lin G, Strunk A, Alloo A. Incidence of hidradenitis suppurativa in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol. 2017; 77: 118–22.
- 10Ingram JR, Jenkins-Jones S, Knipe DW, Morgan CLI, Cannings-John R, Piguet V. Population-based clinical practice research datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa. Br J Dermatol. 2018; 178: 917–24.
- 11Lee JH, Kwon HS, Jung HM, Kim GM, Bae JM. Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population-based study. J Eur Acad Dermatol Venereol. 2018; 32: 1784–90.
- 12Liang YT, Yeh CJ, Huang JY, Wei JC. Epidemiology of hidradenitis suppurativa in Taiwan: a 14-year nationwide population-based study. J Dermatol. 2021; 48: 613–9.
- 13Kim S, Kim MS, You SH, Jung SY. Conducting and reporting a clinical research using Korean healthcare claims database. Korean J Fam Med. 2020; 41: 146–52.
- 14Seo MH, Lee WY, Kim SS, Kang JH, Kang JH, Kim KK, et al. Korean Society for the Study of Obesity (KSSO) 2018 Korean Society for the Study of Obesity guideline for the management of obesity in Korea. J Obes Metab Syndr. 2019; 28: 40–5.
- 15Nam GE, Kim YH, Han K, et al. Obesity fact sheet in Korea, 2019: prevalence of obesity and abdominal obesity from 2009 to 2018 and social factors. J Obes Metab Syndr. 2020; 29: 124–32.
- 16Sherman S, Kridin K, Bitan DT, Leshem YA, Hodak E, Cohen AD. Hidradenitis suppurativa and atopic dermatitis: a 2-way association. J Am Acad Dermatol. 2021; 85: 1473–9.
- 17Rick JW, Alavi A, Hsiao JL, Yosipovitch G, Shi VY. Atopic dermatitis and hidradenitis suppurativa: an under-recognized pair. J Am Acad Dermatol. 2021; 85: e387–8.
- 18Rizzello F, Spisni E, Giovanardi E, Imbesi V, Salice M, Alvisi P, et al. Implications of the westernized diet in the onset and progression of IBD. Nutrients. 2019; 11: 1033. doi:10.3390/nu11051033
- 19Jfri A, Nassim D, O'Brien E, Gulliver W, Nikolakis G, Zouboulis CC. Prevalence of hidradenitis suppurativa: a systematic review and meta-regression analysis. JAMA Dermatol. 2021; 157: 924–31.
- 20Garg A, Kirby JS, Lavian J, Lin G, Strunk A. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol. 2017; 153: 760–4.
- 21Choi E, Chandran NS. Rethinking the female predominance in hidradenitis suppurativa. Int J Dermatol. 2019; 58: e57–8.
- 22Schrader AM, Deckers IE, van der Zee HH, Boer J, Prens EP. Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity. J Am Acad Dermatol. 2014; 71: 460–7.
- 23Revuz JE, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008; 59: 596–601.
- 24Chandran NS, Lee JH, Kurokawa I. Hidradenitis suppurativa in South-East Asia and East Asia. Exp Dermatol. 2021; 30(Suppl 1): 23–6.
- 25Hayama K, Fujita H, Hashimoto T, Terui T, Japanese HSRG. Questionnaire-based epidemiological study of hidradenitis suppurativa in Japan revealing characteristics different from those in Western countries. J Dermatol. 2020; 47: 743–8.
- 26Choi E, Cook AR, Chandran NS. Hidradenitis suppurativa: an Asian perspective from a Singaporean institute. Skin Appendage Disord. 2018; 4: 281–5.
- 27Loo CH, Tan WC, Tang JJ, Khor YH, Manikam MT, Low DE, et al. The clinical, biochemical, and ultrasonographic characteristics of patients with hidradenitis suppurativa in northern peninsular Malaysia: a multicenter study. Int J Dermatol. 2018; 57: 1454–63.
- 28Xu H, Xiao X, Hui Y, Zhang X, He Y, Li C, et al. Phenotype of 53 Chinese individuals with nicastrin gene mutations in association with familial hidradenitis suppurativa (acne inversa). Br J Dermatol. 2016; 174: 927–9.
- 29Pink AE, Simpson MA, Desai N, Dafou D, Hills A, Mortimer P, et al. Mutations in the gamma-secretase genes NCSTN, PSENEN, and PSEN1 underlie rare forms of hidradenitis suppurativa (acne inversa). J Invest Dermatol. 2012; 132: 2459–61.
- 30Miskinyte S, Nassif A, Merabtene F, Ungeheuer MN, Join-Lambert O, Jais JP, et al. Nicastrin mutations in French families with hidradenitis suppurativa. J Invest Dermatol. 2012; 132: 1728–30.
- 31Gulliver W, Alavi A, Wiseman MC, Gooderham MJ, Rao J, Alam MS, et al. Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study. J Eur Acad Dermatol Venereol. 2021; 35: 2431–9.
- 32Campione E, Lanna C, Diluvio L, Cannizzaro MV, Grelli S, Galluzzo M, et al. Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo. Cell Cycle. 2020; 19: 257–67.
- 33Gans MD, Gavrilova T. Understanding the immunology of asthma: pathophysiology, biomarkers, and treatments for asthma endotypes. Paediatr Respir Rev. 2020; 36: 118–27.
- 34Gabryszewski SJ, Hill DA. One march, many paths: insights into allergic march trajectories. Ann Allergy Asthma Immunol. 2021; 127: 293–300.
- 35Woo HD, Shin A, Kim J. Dietary patterns of Korean adults and the prevalence of metabolic syndrome: a cross-sectional study. PLoS One. 2014; 9:e111593.
- 36O'Neill S, O'Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev. 2015; 16: 1–12.
- 37Phan K, Charlton O, Smith SD. Hidradenitis suppurativa and diabetes mellitus: updated systematic review and adjusted meta-analysis. Clin Exp Dermatol. 2019; 44: e126–32.
- 38Bui TL, Silva-Hirschberg C, Torres J, Armstrong AW. Hidradenitis suppurativa and diabetes mellitus: a systematic review and meta-analysis. J Am Acad Dermatol. 2018; 78: 395–402.
- 39Hung CT, Chiang CP, Chung CH, Tsao CH, Chien WC, Wang WM. Increased risk of cardiovascular comorbidities in hidradenitis suppurativa: a nationwide, population-based, cohort study in Taiwan. J Dermatol. 2019; 46: 867–73.
- 40Kimball AB, Sundaram M, Gauthier G, Guérin A, Pivneva I, Singh R, et al. The comorbidity burden of hidradenitis suppurativa in the United States: a claims data analysis. Dermatol Ther (Heidelb). 2018; 8: 557–69.
- 41Shlyankevich J, Chen AJ, Kim GE, Kimball AB. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. J Am Acad Dermatol. 2014; 71: 1144–50.
- 42Egeberg A, Gislason GH, Hansen PR. Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa. JAMA Dermatol. 2016; 152: 429–34.
- 43Park J, Cheon JH. Incidence and prevalence of inflammatory bowel disease across Asia. Yonsei Med J. 2021; 62: 99–108.
- 44Chen WT, Chi CC. Association of hidradenitis suppurativa with inflammatory bowel disease: a systematic review and meta-analysis. JAMA Dermatol. 2019; 155: 1022–7.
- 45Kridin K, Shavit E, Damiani G, Cohen AD. Hidradenitis suppurativa and rheumatoid arthritis: evaluating the bidirectional association. Immunol Res. 2021; 69: 533–40.
- 46Almuhanna N, Finstad A, Alhusayen R. Association between hidradenitis suppurativa and inflammatory arthritis: a systematic review and meta-analysis. Dermatology. 2021; 237: 740–7.
- 47Ross Y, Ballou S. Association of hidradenitis suppurativa with autoimmune disease and autoantibodies. Rheumatol Adv Pract. 2022; 6: rkab108.
- 48Cohen JM, Kridin K, Perez-Chada LM, Merola JF, Cohen AD. Hepatitis B and C among patients with hidradenitis suppurativa: a population-based study. Int J Dermatol. 2022; 61: 84–8.
- 49Schonmann Y, Mansfield KE, Mulick A, Roberts A, Smeeth L, Langan SM, et al. Inflammatory skin diseases and the risk of chronic kidney disease: population-based case-control and cohort analyses. Br J Dermatol. 2021; 185: 772–80.
- 50Seetan K, Eldos B, Saraireh M, Omari R, Rubbai Y, Jayyusi A, et al. Prevalence of low vitamin D levels in patients with hidradenitis suppurativa in Jordan: a comparative cross-sectional study. PLoS One. 2022; 17:e0265672.
- 51Fabbrocini G, Marasca C, Luciano MA, Guarino M, Poggi S, Fontanella G, et al. Vitamin D deficiency and hidradenitis suppurativa: the impact on clinical severity and therapeutic responsivity. J Dermatolog Treat. 2021; 32: 843–4.
- 52Phan K, Huo YR, Smith SD. Hidradenitis suppurativa and psychiatric comorbidities, suicides and substance abuse: systematic review and meta-analysis. Ann Transl Med. 2020; 8: 821.